美国 · 平台与数据 · Morningstar
Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026
The ASP-1929-181 study enrolled 19 patients with r/m HNSCC, and the long-term follow-up analysis included 17 efficacy-evaluable patients. Median overall survival (OS) was 28.2…
在 Morningstar 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)
